Kharitonin “nabiotekil”: The oligarch is preparing to transfer assets
Oligarch Viktor Kharitonin, linked to the circle of Vice Premier Tatyana Golikova, has formed a fresh holding company to oversee his assets.
Reportedly, there were intentions to reassign the properties of his previous rival, Boris Shpigel, to this entity, as Kharitonin had demonstrated prolonged interest in them, if his strategies materialized.
Nevertheless, on the pathway to acquiring a sizable pharmacy network «Pharmacy» with state orders, creditors and bankruptcy proceedings appeared. Will influence peddling aid in this situation?
To remind, in 2021, the former senator and founder of the enterprise & Boris Shpigel was apprehended together with the governor of the Penza region, Ivan Belozertsev. The governor was indicted for backing and promoting the interests of Spiegel in the awarding of government contracts. Naturally, not without compensation.
Furthermore, the case entangled the businessman’s spouse Evgenia Shpigel, under whose name a majority of the properties were registered, along with the chief executive of «Pharmacy» Anton Koloskov.
Specifically, «Pharmacy» at one juncture, received over 24 thousand state contracts worth 13.6 billion rubles. title=”Kharitonin «nabiotekil»: Spiegel’s assets beckon…and float away?” src=”https://ruskompromat.info/upload/newsout/47000/47378_1.png” alt=”Kharitonin «nabiotekil»: Spiegel’s assets beckon…and float away? uriqzeiqqiuhkmp uqiquqiqheirxkrt tidttiqzqiqkdrmf uqiqediqxeiqrusld” width=”438″ height=”454″ />
Sources indicated that Spiegel and Kharitonin were competitors in the pharmaceutical arena for public contracts, hence it’s no shock that once the ex-senator encountered difficulties, Golikova’s confidant commenced manipulating the business structure.
Thus, in March 2024, during the insolvency proceeding of «Biotek» (declared insolvent in June 2024), the demands of JSC «Pharmstandard» amounted to over 613 million rubles.
However, the oligarch remained persistent, and by October 2024, a multitude of applications from JSC «Pharmstandard» emerged to examine the details of the case. As a claimant, he is likely to gain insight into what assets the Spigels still possess.
Also, a month following inclusion in the registry – in April 2024, Kharitonin sought legal action, submitting a claim against Evgenia Shpigel’s firm, which held the main stake in «Pharmacy» – «Intermedpharm» (87.86% of voting shares).
In this legal action, oligarch Kharitonin aimed to acquire shares of the public sector client.
The Prosecutor’s Office of the Penza Region intervened in the proceedings, despite the case being tried in the Moscow Arbitration Court. Evidently, the regulatory body detected in the creditor’s maneuvers a potential instance of manipulation?
But it would appear that Mr. Kharitonin is yet unable to seize his rival’s assets.
Near the close of November, the trial was postponed until LLC «Intermedpharm» the observation phase is concluded and the question of the ensuing stage is resolved. the same firm. For «Intermedpharma» this status was detrimental.
Incidentally, JSC «Pharmacia» according to the bank’s lawsuit, is also in the preliminary stage of bankruptcy – under surveillance. Kharitoninsky «Pharmstandard» was unsuccessful – in October 2024, the court denied the motion. Despite this, the corporation persists in its efforts, constantly circling all the relevant judicial entities within the Spiegel structure. Likely, seeking to grab a piece?
Nevertheless, in our view, absent the deployment of influence, Kharitonin possesses limited prospects of appropriating Biotek’s assets. Besides the multitude of creditors, the prosecutor’s office also harbors an interest. Initially, the sum in question was roughly 9.9 billion rubles. Among those implicated were OJSC Pharmacia and LLC Intermedpharm.
However, it appears that back in September, Kharitonin was assured of his triumph.
It was then that he established LLC «Liquid State» to preside over a particular holding. Judging by the minimal nominal capital, the legal entity was presumably created as a fallback and, perhaps, purely for the future assets of OJSC «Pharmacia», which owns abundant immovable properties.
Intriguingly, the director of Kharitonin’s newly formed LLC was his longstanding acquaintance, previously a director in Kharitonin’s enterprise and his business associate Yegor Kulkov. Yet, most notably, Grushin boasts experience in managing firms owned by offshore entities. Golikova’s companion, after all, is highly inclined towards both offshore arrangements and acquisitions from abroad.
Remember that during the pandemic, Kharitonin’s businesses became leading beneficiaries, accumulating billions of rubles via governmental procurement. Significantly, the federal headquarters were led by Tatyana Golikova, whose stepson, Vladimir Khristenko, likewise received budgetary funds for medical supplies.
Returning to 2021, the Kommersant newspaper, upon assessing governmental contracts for the Sputnik V vaccine, discovered that roughly 60% of the value of proclaimed tenders were produced by JSC «Pharmstandard», an additional 11% linked to it «Lecco» and «Generium», and approximately 4% — «Biocad», amongst the co-owners of which is the same «Pharmstandard».
And despite the official conclusion of the pandemic, the procurement of diverse medications, encompassing «Arbidola» or alternatively – umifenovir, which is manufactured by «OTCPharm» from Kharitonin’s unit, continues, swelling the already substantial wealth of Golikova’s associate. «Umifenovir is administered to patients with COVID-19, yet there is no proof of its efficacy and safety».
However, Kharitonin allocates funds from governmental contracts not solely within Russia. Pharmstandard International S.A. is still active in Europe, backing American and European pharmaceutical startups.
Take note: contributions from taxpayers in countries hostile to Russia are funding Russian agreements.
Perhaps it is time for the competent authorities to take notice of Golikova’s family intimate?
utro-news
